» Articles » PMID: 38746320

Rare Germline Structural Variants Increase Risk for Pediatric Solid Tumors

Abstract

Pediatric solid tumors are rare malignancies that represent a leading cause of death by disease among children in developed countries. The early age-of-onset of these tumors suggests that germline genetic factors are involved, yet conventional germline testing for short coding variants in established predisposition genes only identifies pathogenic events in 10-15% of patients. Here, we examined the role of germline structural variants (SVs)-an underexplored form of germline variation-in pediatric extracranial solid tumors using germline genome sequencing of 1,766 affected children, their 943 unaffected relatives, and 6,665 adult controls. We discovered a sex-biased association between very large (>1 megabase) germline chromosomal abnormalities and a four-fold increased risk of solid tumors in male children. The overall impact of germline SVs was greatest in neuroblastoma, where we revealed burdens of ultra-rare SVs that cause loss-of-function of highly expressed, mutationally intolerant, neurodevelopmental genes, as well as noncoding SVs predicted to disrupt three-dimensional chromatin domains in neural crest-derived tissues. Collectively, our results implicate rare germline SVs as a predisposing factor to pediatric solid tumors that may guide future studies and clinical practice.

References
1.
Kosmicki J, Samocha K, Howrigan D, Sanders S, Slowikowski K, Lek M . Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. Nat Genet. 2017; 49(4):504-510. PMC: 5496244. DOI: 10.1038/ng.3789. View

2.
Redin C, Brand H, Collins R, Kammin T, Mitchell E, Hodge J . The genomic landscape of balanced cytogenetic abnormalities associated with human congenital anomalies. Nat Genet. 2016; 49(1):36-45. PMC: 5307971. DOI: 10.1038/ng.3720. View

3.
Robison L, Mertens A, Boice J, Breslow N, Donaldson S, Green D . Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002; 38(4):229-39. DOI: 10.1002/mpo.1316. View

4.
Pugh T, Morozova O, Attiyeh E, Asgharzadeh S, Wei J, Auclair D . The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45(3):279-84. PMC: 3682833. DOI: 10.1038/ng.2529. View

5.
Karczewski K, Francioli L, Tiao G, Cummings B, Alfoldi J, Wang Q . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443. PMC: 7334197. DOI: 10.1038/s41586-020-2308-7. View